Renal, hormonal, and hemodynamic effects of low-dose infusion of atrial natriuretic factor in acute myocardial infarction

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

Urinary potassium and creatinine clearance were unchanged.

The maximal response of urinary sodium excretion rate after ANF infusion was positively correlated with the basal sodium excretion rate (r = 0.579; p less than 0.05) and inversely correlated with basal plasma renin activity (r = -0.623; p less than 0.05).

Who Took Part

According to the abstract, 12 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, single-blind and placebo-controlled.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the patients, was kept unaware of whether ANP (Atrial Natriuretic Peptide) was given.

The comparison arm used a placebo, so changes seen with ANP (Atrial Natriuretic Peptide) could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Aldosterone, Atrial Natriuretic Factor, Diuretics, Hemodynamics, Infusions, Intra-Arterial, Kidney and Myocardial Infarction.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (American heart journal), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.